As an emerging specialty pharmaceutical company, Pangea Pharmaceuticals, leverages its proven expertise to advance its portfolio of therapeutics and comprehensive support services, all designed to deliver meaningful outcomes for patients.
Learn More
Pangea has a strong commitment to patients by creating access to enhanced, safe, and more affordable medicines. In our effort to improve patient access to life-enhancing prescription medications, we offer a robust portfolio of branded and generic drugs for the pediatric health, pain management, neurological, and ophthalmic segments.
We are constantly evaluating product opportunities to add to our commercial portfolio and late stage product development candidates across various therapeutic categories and dosage forms.
Our focus is to establish meaningful distribution relationships with hospitals, clinics, independent and specialty pharmacies, GPOs, and niche and speciality distributors.
Decades of experience in the US pharmaceutical market provides an unparalleled experience to our partners and access to our global sourcing network of API and Contract Manufacturing partners.
As a US-based specialty pharmaceutical company our streamlined structure promotes decisive action and a rapid go-to-market strategy for our products and partners.
With our combined experience, we bring a wealth of knowledge, expertise, and innovation to deliver exceptional results for our clients
Our pharmaceutical offerings are crafted with the highest standards of quality and safety, ensuring effective and reliable solutions for your health and well-being
Our pharmaceutical products in development are designed to meet current and emerging patient needs as well as bridge gaps in the market
Ergomar® (Ergotamine) is an ergot medication that treats certain types of headaches, including cluster headaches and migraines by tightening blood vessels and calming certain parts of the brain to relieve headache pain.
The acquisition of Ergomar has allowed us to optimize every aspect of the product lifecycle, making improvements from operations to distribution.
Pangea's core strengths and our unwavering commitment to delivering high-quality specialty medications with precision and reliability
Pangea boasts strong distribution relationships with US retail chains, wholesalers, distributors, managed care organizations, mail order pharmacies, and Group Purchasing Organizations (GPOs).
Our robust commercial infrastructure, extensive experience, diverse distribution network, and our ability to execute efficient launches facilitate strategic business alliances and focused collaborations with other specialty pharmaceutical organizations. Please direct partnership inquiries to our commerical team.
| On Market | Category | Type | |
|---|---|---|---|
| Ergomar | Migraine Relief | Commercial | |
| Florafol | Pediatric Vitamin | Commercial | |
| Florafol FE | Pediatric Vitamin | Commercial | |
| Selenious Acid Injection | IV Supplement | Commercial | |
| Phenobarbital Sodium Injection | Barbiturate | Partner | |
| Tetracaine HCl Injection | Neuronal Membrane Stabilizer | Partner | |
| Diclofenac Potassium Tablet | NSAID | Partner | |
| Cataflam | Pain Relief | Partner | |
| Lofena | NSAID | Partner | |
| Papaverine Injection | ED | Partner | |
| IR Tablet | Urology | 2025 Launch | |
| IR Tablet | Corticosteroid | 2025 Launch | |
| IR Tablet | NSAID | 2025 Launch | |
| IR Tablet | NSAID | 2025 Launch | |
| Sterile Opthalmic Ointment | Anticholinergic | 2025 Launch | |
| Sterile Opthalmic Solution | Anticholinergic | 2025 Launch | |
| Oral Solution | Antibiotic | 2025 Launch | |
| IR Capsule | Gallstone Dissolution Agent | 2025 Launch | |
| IR Tablet | Muscle Relaxant/NSAID | 2025 Launch | |
| IR Tablet | Muscle Relaxant/NSAID | 2025 Launch | |
| IR Tablet | Antihistamine | 2025 Launch | |
| Sterile Injectable | Oxidation-Reduction Agent | 2025 Launch | |
| IR Tablet | NSAID | 2025 Launch | |
| IR Tablet | Antihistamine | 2025 Launch | |
| ODT Tablet | Muscle Relaxant | 2026 Launch | |
| ODT Tablet | NSAID | 2026 Launch | |
| ODT Tablet | Antihistamine | 2026 Launch | |
| Sterile Opthalmic Ointment | Antiviral | 2026 Launch |
| On Market | Category | Type | |
|---|---|---|---|
| Ergomar | Migraine Relief | Commercial | |
| Florafol | Pediatric Vitamin | Commercial | |
| Florafol FE | Pediatric Vitamin | Commercial | |
| Selenious Acid Injection | IV Supplement | Commercial |
| On Market | Category | Type | |
|---|---|---|---|
| Phenobarbital Sodium Injection | Barbiturate | Partner | |
| Tetracaine HCl Injection | Neuronal Membrane Stabilizer | Partner | |
| Diclofenac Potassium Tablet | NSAID | Partner | |
| Cataflam | Pain Relief | Partner | |
| Lofena | NSAID | Partner | |
| Papaverine Injection | ED | Partner |
| On Market | Category | Type | |
|---|---|---|---|
| IR Tablet | Urology | 2025 Launch | |
| IR Tablet | Corticosteroid | 2025 Launch | |
| IR Tablet | NSAID | 2025 Launch | |
| IR Tablet | NSAID | 2025 Launch | |
| Sterile Opthalmic Ointment | Anticholinergic | 2025 Launch | |
| Sterile Opthalmic Solution | Anticholinergic | 2025 Launch | |
| Oral Solution | Antibiotic | 2025 Launch | |
| IR Capsule | Gallstone Dissolution Agent | 2025 Launch | |
| IR Tablet | Muscle Relaxant/NSAID | 2025 Launch | |
| IR Tablet | Muscle Relaxant/NSAID | 2025 Launch | |
| IR Tablet | Antihistamine | 2025 Launch | |
| Sterile Injectable | Oxidation-Reduction Agent | 2025 Launch | |
| IR Tablet | NSAID | 2025 Launch | |
| IR Tablet | Antihistamine | 2025 Launch | |
| ODT Tablet | Muscle Relaxant | 2026 Launch | |
| ODT Tablet | NSAID | 2026 Launch | |
| ODT Tablet | Antihistamine | 2026 Launch | |
| Sterile Opthalmic Ointment | Antiviral | 2026 Launch |
